■ GC Labs said on the 16th that it transferred cell genetic testing technology to BioLab. BioLab is a partner diagnostic testing center based in Bahrain. The transferred technology is fluorescence in situ hybridization (FISH). It is a technology that labels DNA base sequences and the like with fluorescence so they can be seen under a microscope.
■ HLB Life Science said on the 16th that it will ship hard-pack syringes for animals for export to the United States. Hard-pack syringes for animals are used for treating livestock, on-site veterinary care, and vaccinations. The syringes are packaged in plastic cases for hygienic storage. The company plans to export a total of 180 t by the end of the year.
■ HUGEL said on the 16th that it held an event in Sweden to promote the hyaluronic acid (HA) filler Revolax. It was the first offline event since the company launched its hyaluronic acid filler in Sweden in 2020. Youssef Haffar of Simply Clinic in the United Kingdom gave a lecture on how to choose filler products and perform procedures anatomically.
■ GC녹십자엠스 said on the 16th that it will become the first in Korea to develop a powder-type hemodialysis concentrate. The company received product approval for manufacturing the powder-type hemodialysis concentrate HD Bisan. The powder formulation is smaller and lighter than conventional liquid formulations, reducing logistics and transportation costs.
■ Dongkook Pharmaceutical said on the 16th that it held a walking donation event with Walkon to support medical expenses for leg diseases among seniors in vulnerable groups. If participants' cumulative step count reaches 1 billion steps, Dongkook Pharmaceutical plans to provide the medical expense support. It will help seniors with leg edema, pain, and varicose veins who have difficulty receiving treatment.
■ STCube said on the 16th that it received approval from the Ministry of Food and Drug Safety for a phase 2 clinical trial plan for Nelmastobart. Nelmastobart is a new drug candidate for lung cancer. The company plans to conduct the trial in patients with advanced or metastatic non-small cell lung cancer.
■ Ildong Pharmaceutical Group said on the 16th that it held a ceremony for Compliance Day 2025. The event aimed to strengthen ethical management and raise compliance awareness. The group conducted a compliance oath for all employees. It designated Compliance Day in 2016.
■ Osstem Implant said on the 16th that it has signed 1,800 interior contracts. The company has been in the interior business since 2016. A company official said, "We take responsibility for construction from start to finish," adding, "We will strengthen trust with customers."
■ Roche Korea said on the 16th that it held an event with the city of Basel, Switzerland, and the Embassy of Switzerland in Korea to discuss healthcare cooperation. Basel is home to about 800 life sciences corporations. The parties shared ways to foster a biohealth hub city and develop the industry.
■ Pfizer Korea said on the 16th that it will run a campaign encouraging simultaneous vaccination for COVID-19 and the flu. It will deliver vaccine information through quizzes to seniors aged 65 and older. A company official said, "We will ensure a stable vaccine supply to create an environment that prevents infectious diseases."